Fukumoto Hisao | Pharmacology Division Natonal Cancer Center Research Instiute
スポンサーリンク
概要
関連著者
-
Saijo N
Medical Oncology National Cancer Center Hospital
-
Fukumoto Hisao
Pharmacology Division Natonal Cancer Center Research Instiute
-
Fukumoto Hisao
Pharmacology Division National Cancer Center Research Institute
-
Saijo N
Division Of Internal Medicine National Cancer Center Hospital East
-
Saijo Nagahiro
国立医薬品食品衛生研究所
-
FUKUMOTO Hisao
Pharmacology Division, National Cancer Center Research Institute
-
Fukumoto H
National Cancer Center Res. Inst.
-
Fukumoto Hisao
国立がんセンター
-
Nishio K
Department Of Genome Biology Kinki University School Of Medicine
-
Kuzuya Nobuaki
国立医薬食品衛生研究所 薬物応答予測プロジェクト
-
NISHIO Kazuto
Pharmacology Division, National Cancer Center Research Institute
-
Saijo Nagahiro
Pharmacology Division, National Cancer Center Research Institute
-
Nishio Kazuto
Pharmacology Division National Cancer Center Research Institute
-
Saijo Nagahiro
Pharmacology Division National Cancer Center Research Institute
-
ARIOKA Hitoshi
Pharmacology Division, National Cancer Center Research Institute
-
FUKUOKA Kazuya
Pharmacology Division, National Cancer Center Research Institute
-
Kanzawa Fumihiko
国立がんセンター
-
Arioka H
National Cancer Center Res. Inst.
-
Arioka Hiroshi
国立がんセンター
-
Arioka Hitoshi
国立がんセンター中央病院
-
Arioka Hitoshi
Pharmacology Division National Cancer Center Research Institute
-
Fukuoka Kazuya
Pharmacology Division National Cancer Center Research Institute
-
Kaniwa N
Department Of Genome Biology Kinki University School Of Medicine
-
ISHIDA Tomoyuki
Pharmacology Division, National Cancer Center Research Institute
-
KUROKAWA Hirokazu
Pharmacology Division, National Cancer Center Research Institute
-
Kanzawa Fumihiko
Pharmacology:pathology Division National Cancer Center Research Institute:surgery Division:departmen
-
Ishida Tomoyuki
Pharmacology Division National Cancer Center Research Institute
-
Ishida Tomoyuki
国立がんセンター
-
Fukuoka K
National Cancer Center Res. Inst.
-
Kurokawa Hirokazu
Pharmacology Division National Cancer Center Research Institute
-
Kurokawa Hirokazu
国立がんセンター
-
NISHIO Kazuto
Department of Genome Biology, Kinki University School of Medicine
-
NOMOTO Taisuke
Pharmacology Division, National Cancer Center Research Institute
-
Nomoto T
Pharmacology Division National Cancer Center Research Institute
-
Nomoto Taisuke
国立がんセンター
-
Nomoto Taisuke
Pharmacology Division National Cancer Center Research Institute
-
Saijo Nagahiro
Department Of Internal Medicine National Cancer Center Hospital
-
Ohe Yuichiro
Medical Oncology National Cancer Center Hospital
-
YOKOTE Hideyuki
Shien-Laboratory, National Cancer Center Hospital
-
YOKOTE Hideyuki
Pharmacology Division, National Cancer Center Research Institute
-
Yokote Hideyuki
近畿大学 医学部ゲノム生物学
-
Yokote H
Shien-laboratory National Cancer Center Hospital
-
Yokote Hideyuki
Department Of Genome Biology Kinki University School Of Medicine
-
Yokote Hideyuki
Pharmacology Division National Cancer Center Research Institute
-
HEIKE Yuji
Pharmacology Division, National Cancer Center Research Institute
-
Fukuoka Kazuya
国立がんセンター
-
Heike Yuji
国立がんセンター中央病院
-
Heike Y
Pharmacology Division National Cancer Center Research Institute
-
Heike Yuji
Pharmacology Division National Cancer Center Research Institute
-
Fukuoka K
Pharmacology Division National Cancer Center Research Institute
-
MIYAMOTO Ken-ichi
Department of Pharmacology and Pharmaceutics, Graduate School of Natural Science and Technology, Kan
-
SAIJO Nagahiro
Medical Oncology Division, National Cancer Center Hospital
-
OKA MIKIO
Second Department of Internal Medicine, Nagasaki University School of Medicine
-
Ohe Yuichiro
Department Of Medical Oncology National Cancer Center Hospital
-
Ohe Yuichiro
Department Of Internal Medicine National Cancer Center Hospital
-
YOKOTA Jun
Biology Division, National Cancer Center Research Institute
-
Nishio Kazuto
近畿大学 医学部ゲノム生物学
-
ABE Shosaku
Third Division, Department of Internal Medicine, Sapporo Medical University School of Medicine
-
IWAMOTO Yasuo
Pharmacology Division, National Cancer Center Research Institute, Medical Oncology Division, Nationa
-
YOSHIMATSU Kentaro
Tsukuba Research Laboratories, Eisai Co., Ltd.
-
YAMAKIDO Michio
The Second Department of Internal Medicine, Hiroshima University
-
ADACHI Jun-ichi
Biology Division, National Cancer Center Research Institute
-
TOMONARI Akira
Pharmacology Division, National Cancer Center Research Institute
-
NARITA Nobuhiro
Second Department of Internal Medicine, Nara Medical University
-
NISHIO Makoto
Division of Internal Medicine, Cancer Institute Hospital
-
FUKUDA Minoru
Department of Medical Oncology, National Cancer Center Hospital
-
INOMATA Motoko
Pharmacology Division, National Cancer Center Research Institute
-
KANZAWA Fumihiko
Pharmacology Division, National Cancer Center Research Institute
-
Yamakido Michio
The Second Department Of Internal Medicine Hiroshima University School Of Medicine
-
Tomonari Akira
Pharmacology Division National Cancer Center Research Institute
-
Kanzawa Fumihiko
Pharmacology Division National Cancer Center Research Institute
-
Abe Shosaku
Third Department Of Internal Medicine Sapporo Medical University School Of Medicine
-
Inomata Motoko
Pharmacology Division National Cancer Center Research Institute
-
Inomata Motoko
国立がんセンター中央病院
-
Yoshimatsu Kentaro
Tsukuba Research Laboratories Eisai Co. Ltd.
-
Yoshimatsu Kentaro
国立がんセンター
-
Podack E.
Department Of Microbiology And Immunology University Of Miami School Of Medicine
-
Olsen K.j.
Department Of Microbiology And Immunology University Of Miami School Of Medicine
-
Saijo Nagahiro
Medical Oncology Division National Cancer Center
-
TATSUMI Yasuaki
Pharmacology Division, National Cancer Center Research Institute
-
IKEDA Shun-ichi
Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.
-
OHIRA Tatsuo
Pharmacology Division, National Cancer Center Research Institute
-
Ohe Yuichiro
Pharmacology Division, National Cancer Canter Research Institute
-
NARUSE Ichiro
Pharmacology Division, Natonal Cancer Center Research Instiute
-
SAIJO Nagahito
Pharmacology Division, Natonal Cancer Center Research Instiute
-
NISHIO Kazuta
Pharmacology Division, Natonal Cancer Center Research Instiute
-
Tatsumi Yasuaki
Pharmacology Division National Cancer Center Research Institute
-
Yamakido Michio
The Second Department Of Internal Medicine Hiroshima University
-
Miyamoto Ken-ichi
Department Of Pharmacology And Pharmaceutics Graduate School Of Natural Science And Technology Kanaz
-
Fukuda Minoru
Department Of Medical Oncology National Cancer Center Hospital
-
Oka Mikio
Second Department Of Internal Medicine Nagasaki University School Of Medicine
-
Abe S
Keio Univ. Tokyo
-
Ohira Tatsuo
Pharmacology Division National Cancer Canter Research Institute
-
Nishio Kazuta
Pharmacology Division Natonal Cancer Center Research Instiute
-
Saijo Nagahito
Pharmacology Division Natonal Cancer Center Research Instiute
-
Fukuda Minoru
Department Of Anatomy Kyorin University School Of Medicine
-
Iwamoto Yasuo
Pharmacology Division National Cancer Center Research Institute Medical Oncology Division National C
-
Adachi J
Biology Division National Cancer Center Research Institute
-
Nishio Makoto
Division Of Internal Medicine Cancer Institute Hospital
-
Ikeda Shun-ichi
Tokyo Research Laboratories Kyowa Hakko Kogyo Co. Ltd.
-
Yokota J
National Cancer Center Res. Inst. Tokyo
-
Yokota Jun
Biology Division National Cancer Center Research Institute
-
Miyamoto Ken-ichi
Department Of Applied Pharmacology Faculty Of Pharmaceutical Sciences Hokuriku University
-
Naruse Ichiro
Pharmacology Division Natonal Cancer Center Research Instiute
-
Narita N
Shibaura Inst. Of Technol. Tokyo
-
Narita Nobuhiro
Second Department Of Internal Medicine Nara Medical University
著作論文
- Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA-transfected Human Lung Cancer Cells
- Preferential Binding of E7010 to Murine β3-Tubulin and Decreased β3-Tubulin in E7010-resistant Cell Lines
- p16^ Expression Is Associated with the Increased Sensitivity of Human Non-small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors
- Interferon-γ-inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
- Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ-Glutamylcysteine Synthetase Gene
- A Topoisomerase II Inhibitor, NK109, Induces DNA Single- and Double-strand Breaks and Apoptosis
- Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1-Phenylpropenone Derivative, AM-132, by Tumor Necrosis Factor-α or Interleukin-6
- Immunotherapy by intra-peritoneal intra-peritoneal injection of interleukin-2 gene transduced ling cancer cell line.
- Enhanced Anti-tumor Effect of Trastuzumab in Combination with Cisplatin